VivoSeq
Oncology

Advanced or Metastatic Solid Tumors

6

Pipeline Programs↗

76

Active Trials↗

60

Companies Involved↗

Advanced or Metastatic Solid Tumors is an early-stage landscape with 6 programs across 60 companies. The most active players are Amgen, Merck & Co., IDEAYA Biosciences.

Intelligence

Pipeline Metrics

Competitive Density

57/100

Pipeline Velocity

41/100

Mech. Concentration

50/100

Completion Rate

57/100

Attrition Rate

20/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Amgen logo

Amgen

2 programs

Phase 1Merck & Co. logo

Merck & Co.

1 program

Phase 1I

IDEAYA Biosciences

1 program

Phase 1Bristol-Myers Squibb logo

Bristol-Myers Squibb

0 programs

PreclinicalPfizer logo

Pfizer

0 programs

PreclinicalIncyte logo

Incyte

0 programs

Preclinical

Pipeline

Programs by Phase

Analysis

Modality Breakdown

60%

Small molecule

3 of 5 classified programs — the dominant modality here.

40%ALL OTHERSMonoclonal antibody240%

Small molecule leads; the ring shows all 5 classified programs, each share of the total. Modality classified for 83% of 6 pipeline programs.

Analysis

Trial Status

164

clinical trials

Recruiting45 · 27%
Completed43 · 26%
Terminated29 · 18%
Active, not recruiting23 · 14%
Unknown status13 · 8%
Not yet recruiting8 · 5%
Other3 · 2%

Clinical Trials

Trial Activity

164 trials

A Phase 1 Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of EU103 in Advanced or Metastatic Solid Tumors That Have Failed Standard Therapy
Recruiting·EEutilex·Phase 1·NCT05798026·15 enrolled
A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors
Recruiting·Pfizer logoPfizer·Phase 1·NCT07318805·260 enrolled
Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors
Recruiting·OOlema Pharmaceuticals, Inc.·Phase 1·NCT06784193·180 enrolled
A Study With ABL103 in Subjects With Advanced or Metastatic Solid Tumors
Recruiting·AABL Bio, Inc.·Phase 1·NCT06126666·96 enrolled
Dose Escalation and Expansion Study Evaluating ODC-IL2 in Adult Patients With Advanced or Metastatic Solid Tumors
Recruiting·TTrutino Biosciences Inc.·Phase 1·NCT06770764·50 enrolled
Dose Escalation and Expansion Study of HM97662 in Advanced or Metastatic Solid Tumors
Recruiting·Hanmi Pharmaceutical Company Limited logoHanmi Pharmaceutical Company Limited·Phase 1·NCT05598151·170 enrolled
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
Recruiting·Incyte logoIncyte·Phase 1·NCT06179160·710 enrolled
Evaluation of RAS Inhibitor Treatment in Participants With Advanced or Metastatic Solid Tumors Harboring RAS Mutations
Recruiting·AAdlai Nortye Biopharma Co., Ltd.·Phase 1·NCT07252479·91 enrolled
Phase Ia/Ib Study of CKD-512 Alone and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Solid Tumors
Recruiting·Chong Kun Dang Pharmaceutical logoChong Kun Dang Pharmaceutical·Phase 1·NCT07215637·60 enrolled
A Study of JZP815 Oral Capsules in Adult Participants With Advanced or Metastatic Solid Tumors Harboring Mitogen Activated Protein Kinase (MAPK) Pathway Alterations to Investigate the Safety, Dosing, and Antitumor Activity of JZP815
Recruiting·Jazz Pharmaceuticals logoJazz Pharmaceuticals·Phase 1·NCT05557045·332 enrolled
A Study of DC50292A Tablet in Patients With MTAP-deleted Advanced or Metastatic Solid Tumors
Recruiting·HHeronova Pharmaceuticals·Phase 1·NCT07071090·32 enrolled
A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
Recruiting·Eli Lilly logoEli Lilly·Phase 1·NCT06561685·340 enrolled
A Study of ERAS-4001 in Patients With Advanced or Metastatic Solid Tumors.
Recruiting·EErasca, Inc.·Phase 1·NCT07021898·200 enrolled
Dose Escalation and Expansion Study of HM16390 Alone or With Pembrolizumab in Advanced or Metastatic Solid Tumors
Recruiting·Hanmi Pharmaceutical Company Limited logoHanmi Pharmaceutical Company Limited·Phase 1·NCT06724016·292 enrolled
Study of PF-07248144 in Advanced or Metastatic Solid Tumors
Recruiting·Pfizer logoPfizer·Phase 1·NCT04606446·320 enrolled
Page 1 of 11

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)